martes, 10 de diciembre de 2013

Study Reveals New Targets for Parkinson's Disease - NIH Research Matters - National Institutes of Health (NIH)

Study Reveals New Targets for Parkinson's Disease - NIH Research Matters - National Institutes of Health (NIH)

Study Reveals New Targets for Parkinson's Disease

Scientists used a novel approach to identify dozens of genes that may contribute to Parkinson’s disease. The discoveries may also yield insights into other disorders that involve mitochondria, the organelles that serve as power plants for our cells.
Green background in cell doesn’t overlap with red clusters.
Turning off some genes, like HSPAI1L, inhibits parkin (green) from tagging damaged mitochondria (red). Image by the Youle lab, courtesy of Nature.
Mitochondria convert compounds derived from food into the molecules that cells use for energy. Defects in mitochondrial function can lead to disease and have been associated with certain neurological disorders, including Parkinson’s disease, Charcot-Marie-Tooth syndrome, and the ataxias.
Some cases of Parkinson’s disease have been linked to mutations in the gene that codes for parkin, a protein that cells use to tag damaged mitochondria as waste. Once tagged, damaged mitochondria are degraded by lysosomes, the cell’s trash disposal system. Known mutations in parkin prevent this tagging and result in the accumulation of unhealthy mitochondria.
A team led by Dr. Richard Youle at NIH’s National Institute of Neurological Disorders and Stroke (NINDS) used RNA interference (RNAi) to screen for genes that help parkin tag damaged mitochondria. RNAi is a natural process that cells use to turn down, or silence, the activity of specific genes. Since its discovery in 1998, scientists have used RNAi as a tool to investigate the function of genes and their involvement in health and disease.
Working in collaboration with RNAi expert Dr. Scott Martin’s team at NIH’s National Center for Advancing Translational Sciences (NCATS), the researchers used robotics to introduce small interfering RNAs (siRNAs) into human cells to individually turn off nearly 22,000 genes. Using automated microscopy, they then examined how silencing each gene affected the ability of parkin to tag mitochondria. The results appeared online on November 24, 2013, in Nature.
The researchers found that dozens of candidate genes affected parkin tagging. Turning off some, such as TOMM7 and HSPAI1L, inhibited parkin tagging. Switching off others, including BAG4 and SIAH3, enhanced tagging. Many of these genes have been found in previous studies to encode mitochondrial proteins or to help regulate ubiquitination, a process that cells use to mark proteins for degradation.
The researchers tested one of the genes, TOMM7, in human nerve cells. Turning off TOMM7 inhibited tagging of mitochondria in these cells as well. The results suggest that many of the genes identified in this study may work like quality control agents in a variety of cell types, including neurons.
“We discovered a network of genes that may regulate the disposal of dysfunctional mitochondria, opening the door to new drug targets for Parkinson’s disease and other disorders,” Youle says.

Related Links:

Reference: High-content genome-wide RNAi screens identify regulators of parkin upstream of mitophagy. Nature. 2013 Nov 24. doi: 10.1038/nature12748. [Epub ahead of print]. PMID: 24270810.
Funding: NIH’s National Institute of Neurological Disorders and Stroke (NINDS), National Center for Advancing Translational Sciences (NCATS), and National Institute of General Medical Sciences (NIGMS); and the Japan Society for Promotion of Science Postdoctoral Fellowship for Research Abroad.

No hay comentarios:

Publicar un comentario